ReviewBritish journal of pharmacology2013
Non-invasive molecular imaging for preclinical cancer therapeutic development.
Review in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Preliminary assessment of biodistribution and targeting of the fluorescent molecular probe Cy7-SYL3C in an EpCAM-positive colorectal cancer mouse model.Scientific reports · 2026Article
- MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models.Pigment cell & melanoma research · 2025Article
- Targeted Biodegradable Near-Infrared Fluorescent Nanoparticles for Colorectal Cancer Imaging.ACS applied bio materials · 2024Article
- Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors.Molecular therapy. Oncology · 2024Article
- Modification of nanodiamonds for fluorescence bioimaging.RSC advances · 2024Article
- Fluorescent-Nanoparticle-Impregnated Nanocomposite Polymeric Gels for Biosensing and Drug Delivery Applications.Gels (Basel, Switzerland) · 2023Review
- Whole-body bioluminescence imaging of T-cell response in PDAC models.Frontiers in immunology · 2023Article
- Web-Based Application for Biomedical Image Registry, Analysis, and Translation (BiRAT).Tomography (Ann Arbor, Mich.) · 2022Article
- Spatial frequency domain imaging for monitoring immune-mediated chemotherapy treatment response and resistance in a murine breast cancer model.Scientific reports · 2022Article
- Performance evaluation of the IRIS XL-220 PET/CT system, a new camera dedicated to non-human primates.EJNMMI physics · 2022Article
- Polyaminoacid Based Core@shell Nanocarriers of 5-Fluorouracil: Synthesis, Properties and Theranostics Application.International journal of molecular sciences · 2021Article
- Performance of nanoScan PET/CT and PET/MR for quantitative imaging ofEJNMMI research · 2021Article
- Synthesis of Zr-89-Labeled Folic Acid-Conjugated Silica (SiOMaterials (Basel, Switzerland) · 2021Article
- PESIN Conjugates for Multimodal Imaging: Can Multimerization Compensate Charge Influences on Cell Binding Properties? A Case Study.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Investigating T Cell Immunity in Cancer: Achievements and Prospects.International journal of molecular sciences · 2021Review
- Noninvasive Imaging for Assessment of the Efficacy of Therapeutic Agents for Hepatocellular Carcinoma.Molecular imaging and biology · 2020Review
- Mouse Tumor Models for Advanced Cancer Immunotherapy.International journal of molecular sciences · 2020Review
- Understanding the Uptake of Nanomedicines at Different Stages of Brain Cancer Using a Modular Nanocarrier Platform and Precision Bispecific Antibodies.ACS central science · 2020Article
- Kinetic modeling and analysis of dynamic bioluminescence imaging of substrates administered by intraperitoneal injection.Quantitative imaging in medicine and surgery · 2020Article
- Multiplexed non-invasive tumor imaging of glucose metabolism and receptor-ligand engagement using dark quencher FRET acceptor.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Molecular and non-invasive imaging are rapidly emerging fields in preclinical cancer drug discovery. This is driven by the need to develop more efficacious and safer treatments, the advent of molecular-targeted therapeutics, and the requirements to reduce and refine current preclinical in vivo models. Such bioimaging strategies include MRI, PET, single positron emission computed tomography, ultrasound, and optical approaches such as bioluminescence and fluorescence imaging. These molecular imaging modalities have several advantages over traditional screening methods, not least the ability to quantitatively monitor pharmacodynamic changes at the cellular and molecular level in living animals non-invasively in real time. This review aims to provide an overview of non-invasive molecular imaging techniques, highlighting the strengths, limitations and versatility of these approaches in preclinical cancer drug discovery and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.